Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2 study consists of two parts. The purpose of Part 1 of the study is to examine
the safety and tolerability of AKN-028 and to determine the recommended dose of AKN-028 for
further evaluation in Part 2 of the study in patients with Acute Myelogenous Leukemia (AML).
The purpose of Part 2 of the study is to determine safety and efficacy in patients with AML.